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ABSTRACT Electrophysiological data suggest that alterations in the function of one
glutamate receptor subtype may affect the function of other subtypes. Further, previous
studies have demonstrated that NMDA receptor antagonists affect NMDA and kainate
receptor expression in rat hippocampus. In order to address the mutual regulation of
NMDA, AMPA, and kainate receptor expression in rat hippocampus, we conducted two
experiments examining the effects of NMDA and non-NMDA glutamate receptor mod-
ulators on NMDA, AMPA, and kainate receptor expression using in situ hybridization
and receptor autoradiography. NMDA receptor expression was preferentially affected by
systemic treatments, as all drugs significantly altered [3H]MK-801 binding, and several
drugs increased [3H]ifenprodil binding. GYKI52466 and aniracetam treatments resulted
in changes in both [3H]ifenprodil binding and NR2B mRNA levels, consistent with the
association of this subunit and binding site in vitro. There were more modest effects on
AMPA and kainate receptor expression, even by direct antagonists. Together, these data
suggest that ionotropic glutamate receptors interact at the level of expression. These
data also suggest that drug regimens targeting one ionotropic glutamate receptor
subtype may indirectly affect other subtypes, potentially producing unwanted side
effects. Synapse 38:294–304, 2000. © 2000 Wiley-Liss, Inc.
INTRODUCTION
Ionotropic glutamate receptors are multimeric asso-
ciations of subunits that form ligand-gated ion chan-
nels and are identified by their selective agonists N-
methyl-D-aspartate (NMDA), a-amino-3-hydroxy-5-
methylisoxazoleproprionic acid (AMPA), and kainate.
The AMPA receptor subunits are derived from a family
of four genes termed gluR1–gluR4, while kainate re-
ceptor subunits are derived from genes for the low-
affinity gluR5–gluR7 and high-affinity KA1–KA2 sub-
units (Hollmann and Heinemann, 1994). The NMDA
receptor subunits are encoded by five genes termed
NR1 and NR2A–NR2D (Hollmann and Heinemann,
1994). NR1 is expressed as one of eight isoforms, due to
the alternative splicing of exons 5, 21, and 22 (Durand
et al., 1993; Hollmann and Heinemann, 1994). Because
subunits of the same subtype can coassemble into mul-
tiple potential combinations, there may be significant
heterogeneity within a given subtype. Further, the
pharmacological regulation of glutamate receptors de-
pends on the unique combination of binding sites on
the assembled receptor, which are associated with the
presence of selected subunits (Hollmann and Heine-
mann, 1994). For example, there is a site on the NMDA
receptor for the binding of glutamate, and competitive
antagonists of the receptor, like CGP39653, probably
compete with glutamate at this site. The presence of
NR2A in the final receptor is associated with NMDA
receptors, showing a greater affinity for CGP39653. A
separate glycine binding site must also be occupied
before glutamate can activate the ion channel and
MDL105,519 is an antagonist of this site. This ligand is
associated with NR1 expression. In addition, there is a
site within the ion channel itself associated with the
binding of noncompetitive antagonists of the NMDA
receptor, such as MK-801. NMDA receptors containing
NR2A or NR2B subunits show a greater affinity for
MK-801 than those containing NR2C or NR2D. Fi-
nally, there is a polyamine modulatory site that is
antagonized by the binding of ifenprodil, either directly
or through another allosteric site, which is associated
with the NR2B subunit. Assembled AMPA receptors
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also contain several binding sites, one for glutamate,
another at which competitive antagonists such as
CNQX act (through an allosteric mechanism that af-
fects glutamate binding), and yet another where desen-
sitization modulators exert their influence. Little is
known how subunit composition affects AMPA agonist
and antagonist binding. Similarly, kainate receptors
contain a glutamate binding site, although other bind-
ing sites have not been as well characterized. Subunit
composition represents a mechanism that may influ-
ence the functional properties of ionotropic glutamate
receptors.
Electrophysiological data suggest that alterations in
the function of one glutamate receptor subtype may
affect the function of other subtypes. Kainate receptors
appear to decrease inhibitory (GABAergic) tone
(Clarke et al., 1997; Rodriguez-Moreno et al., 1997),
which affects postsynaptic AMPA and NMDA receptor-
mediated activity (He et al., 1998). Further, AMPA
receptors appear to play a permissive role for NMDA
receptor activity (Wheal and Thomson, 1995). NMDA
receptors are blocked by magnesium ions at physiolog-
ical concentrations, which is voltage-dependent. Mag-
nesium ions are extruded from the ion channel with the
partial depolarization of the cell membrane resulting
from AMPA receptor activation. Therefore, it might be
expected that altered activity mediated by one subtype
of ionotropic glutamate receptor may result in compen-
satory changes in the activity of the other subtypes.
These changes may include alterations in receptor
composition or receptor number.
Several previous studies have demonstrated that un-
competitive NMDA receptor antagonists affect NMDA
and kainate receptor expression in the hippocampus
(e.g., Gao and Tamminga, 1995, 1996), but few studies
have examined the effects of drugs that modulate
AMPA or kainate receptors. We performed two exper-
iments that utilized systemic treatment with NMDA,
AMPA, and kainate receptor antagonists, and deter-
mined the expression of ionotropic glutamate receptors
using in situ hybridization and receptor autoradiogra-
phy. These techniques allow us to examine both sub-
unit composition and binding properties of final assem-
bled receptors. Our overall hypothesis was modulation
of ionotropic glutamatergic activity via one receptor
subtype would result in alterations in the expression of
all three ionotropic glutamate receptors in the hip-
pocampus.
MATERIALS AND METHODS
Animal treatments and preparation
Adult, male Sprague-Dawley rats (250 gm) were
housed five to a cage with food and water ad libitum. In
the MK-801 experiment (Experiment 1), one set of five
rats was injected s.c. with either 0.3 mg/kg, 1.0 mg/kg,
or sterile H2O vehicle for 1, 2, 5, or 10 days. Animals
were sacrificed 2 h after their last injection, their
brains immediately removed, and frozen in isopentane.
The brains were stored at 280°C until sectioned. For
the AMPA/kainate receptor modulator experiment (Ex-
periment 2), groups of 10 rats were treated with 7 daily
subcutaneous injections of either DMSO vehicle,
aniracetam (20 mg/kg), NBQX (7 mg/kg), CNQX (10
mg/kg), GYKI 52466 (8 mg/kg), or riluzole (4 mg/kg)
(Table I). Twenty-four hours after the last injection, the
animals were sacrificed, their brains immediately re-
moved, and frozen in isopentane. The brains were
stored at 280°C until sectioned. For both experiments,
doses of ionotropic glutamate receptor modulators were
chosen based on previous studies that demonstrated
biochemical or behavioral changes resulting from sub-
chronic treatment (Healy and Meador-Woodruff, 1996;
Himori et al., 1995; Malgouris et al., 1989; Mead and
Stephens, 1998; Romettino et al., 1991; Vanover, 1998;
Wahl et al., 1993; Yamada et al., 1985).
Each brain was thawed for 30 min to a temperature
of 220°C and mounted for cryostat sectioning. Ten mm
sections were obtained throughout each brain and
thaw-mounted on polylysine-subbed microscope slides.
The slides were dessicated and stored at 280°C until
used for in situ hybridization and receptor autoradiog-
raphy.
In situ hybridization
Riboprobes were synthesized from linearized plas-
mid DNA containing subclones of these ionotropic glu-
tamate receptor subunits, as previously described
(Meador-Woodruff et al., 1997). The subclones for
NMDA, AMPA, and kainate receptor subunits are
summarized in Table II. Briefly, 100 mCi of [35S]-UTP
was dried and 2.0 ml 53 transcription buffer, 1.0 ml 0.1
M DTT, 1.0 ml each of 10 mM ATP, CTP, and GTP, 2.0
ml linearized plasmid DNA, 0.5 ml RNase inhibitor, and
1.5 ml T3 or T7 RNA polymerase enzyme were added to
the tube and incubated for 2 h at 37°C. One ml DNase
(RNase-free) was then added and the mixture was in-
cubated for 15 min at room temperature. The reaction
mixture was sieved through a 1 cc syringe containing
G-50 Sephadex equilibrated in Tris buffer (100 mM
Tris-HCl, pH 7.5, 12.5 mM EDTA, pH 8.0, 150 mM
NaCl, and 0.2% SDS) and 100 ml fractions were eluted.
Two slides per animal for each probe were removed
from 280°C storage and placed in 4% (weight:vol)
formaldehyde at room temperature for 1 h. The slides
TABLE I. Mechanism of action of the drugs used
in the two experiments
Drug Mechanism of action
MK-801 NMDA receptor antagonist
Aniracetam AMPA receptor densensitization inhibitor
GYKI52466 AMPA receptor densensitization facilitator
NBQX Selective competitive AMPA receptor antagonist
CNQX Less selective competitive AMPA/kainate
receptor antagonist
Riluzole Glutamate release inhibitor
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were then washed in 23 SSC (300 mM NaCl/30 mM
sodium citrate, pH 7.2) three times for 5 min each. The
slides were then washed in deionized H2O for 1 min
before being placed in 0.1 M triethanolamine, pH 8.0/
acetic anhydride, 400:1 (vol:vol), on a stir plate for 10
min. The final wash was in 23 SSC buffer for 5 min,
followed by dehydration through graded alcohols and
air drying. A cover slip with 30 ml of riboprobe (1
million dpm)/75% formamide buffer/0.01 M DTT was
placed on each slide. Slides were placed in a covered
tray with filter paper saturated with 75% formamide
buffer and incubated at 55°C overnight.
The next day the coverslips were removed and the
slides were placed in 23 SSC for 5 min, followed by
RNase (200 mg/ml in 10 mM Tris-HCl, pH 8.0/0.5 M
NaCl) at 37°C for 30 min. The slides then underwent
the following washes: 23 SSC at room temperature for
10 min; 13 SSC for 10 min at room temperature; 0.53
SSC at 55°C for 60 min; and 0.53 SSC for 10 min at
room temperature. The slides were dehydrated in
graded ethanol solutions and air dried. They were
placed in X-ray cassettes and apposed to Kodak XAR-5
film for 1–35 days.
Receptor autoradiography
The conditions used to determine binding to NMDA,
AMPA, and kainate receptors are summarized below:
[3H]MK-801 (intrachannel site of the NMDA
receptor)
The slides were thawed to room temperature and
placed in 5 mM Tris-Cl with 50 mM L-glutamate, 50 mM
spermine, and 50 mM glycine (pH 7.6) at 4°C (Huettner
and Bean, 1987; Ransom and Stec, 1988). After 10 min,
the slides were dipped quickly in water and air-dried
using the “cool” setting of a blow dryer. The [3H]MK-
801 was diluted to 3 nM (;3 3 Kd) using 5 mM Tris-
Cl/50 mM L-glutamate/50 mM spermine/50 mM glycine
buffer. For each animal, two slides were incubated with
[3H]MK-801 to determine total binding and one slide
with [3H]MK-801 plus 0.01 mM unlabeled MK-801 to
determine nonspecific binding. The slides were incu-
bated for 60 min at room temperature. After incuba-
tion, the slides were washed for 30 sec each in three
4°C washes of 5 mM Tris-Cl, then quickly dipped in 4°C
water and air-dried using the “cool” setting of a blow
dryer. The slides were placed in autoradiography cas-
settes and apposed to Amersham [3H]Hyperfilm for 7
days.
[3H]Ifenprodil (polyamine site of the NMDA
receptor)
The slides were thawed to room temperature and
placed in 50 mM Tris-Cl (pH 7.4) at room temperature
(Hashimoto et al., 1994). After 15 min, the slides were
dipped quickly in water and air-dried using the “cool”
setting of a blow dryer. The [3H]ifenprodil was diluted
to 20 nM (;3 3 Kd) using 50 mM Tris-Cl with 3 mM
GBR-12909 (to block sigma receptors). For each sub-
ject, two slides were incubated with [3H]ifenprodil to
determine total binding, and one slide with [3H]ifen-
prodil plus 10 mM spermine to determine nonspecific
binding. The slides were incubated for 120 min at 4°C.
After incubation, the slides were washed for 30 sec
each in three 4°C washes of 50 mM Tris-Cl, then
quickly dipped in 4°C water and air-dried using the
“cool” setting of a blow dryer. The slides were placed in
autoradiography cassettes and apposed to Amersham
[3H]Hyperfilm for 2 days.
[3H]CGP39653 (glutamate site of the NMDA
receptor)
The slides were thawed to room temperature and
placed in 50 mM Tris-Cl (pH 8.0) at room temperature
(Sills et al., 1991; White and Vogel, 1996). After 45 min,
the slides were dipped quickly in water and air-dried
using the “cool” setting of a blow dryer. The
[3H]CGP39653 was diluted to 20 nM (;3 3 Kd) using
50 mM Tris-Cl. For each animal, two slides were incu-
bated with [3H]CGP39653 to determine total binding
and one slide with [3H]CGP39653 plus 1 mM gluta-
mate to determine nonspecific binding. The slides were
incubated for 45 min at room temperature. After incu-
bation, the slides were washed for 1 sec each in three
4°C washes of 50 mM Tris-Cl, then quickly dipped in
4°C water and air-dried using the “cool” setting of a
blow dryer. The slides were placed in autoradiography
cassettes and apposed to Amersham [3H]Hyperfilm for
2 weeks.
[3H]MDL105,519 (glycine site of the NMDA
receptor)
The slides were thawed to room temperature and
placed in 50 mM Tris-Cl (pH 6.0) at room temperature
(Baron et al., 1996; Siegel et al., 1996). After 30 min,
the slides were dipped quickly in water and air-dried
using the “cool” setting of a blow dryer. The
[3H]MDL105,519 was diluted to 12 nM (;3 3 Kd) using
50 mM Tris-Cl. For each animal, two slides were incu-
TABLE II. Probes used for in situ hybridization studies
Probe Length (bp) Region encoded
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bated with [3H]MDL105,519 to determine total binding
and one slide with [3H]MDL105,519 plus 50 mM gly-
cine to determine nonspecific binding. The slides were
incubated for 60 min at room temperature. After incu-
bation, the slides were washed for 60 sec each in three
4°C washes of 50 mM Tris-Cl, then quickly dipped in
4°C water and air-dried using the “cool” setting of a
blow dryer. The slides were placed in autoradiography
cassettes and apposed to Amersham [3H]Hyperfilm for
3 days.
[3H]AMPA (glutamate site of the AMPA
receptor)
The slides were thawed to room temperature and
placed in 50 mM Tris-citrate (pH 7.4) at room temper-
ature (Healy et al., 1998; Nielsen et al., 1988). After 30
min, the slides were dipped quickly in water and air-
dried using the “cool” setting of a blow dryer. The
[3H]AMPA was diluted to 18 nM (;3 3 Kd) using 50
mM Tris-citrate with 0.1 M KSCN. For each animal,
two slides were incubated with [3H]AMPA to deter-
mine total binding and one slide with [3H]AMPA plus
10 mM CNQX as blocker to determine nonspecific bind-
ing. The slides were incubated for 45 min at 4°C. After
incubation, the slides were washed for 5 sec each in
three 4°C washes of 50 mM Tris-citrate, then quickly
dipped in 4°C water and air-dried using the “cool”
setting of a blow dryer. The slides were placed in au-
toradiography cassettes and apposed to Amersham
[3H]Hyperfilm for 3 weeks.
[3H]Kainate (glutamate site of the kainate
receptor)
The slides were thawed to room temperature and
placed in 50 mM Tris-citrate (pH 7.4) at room temper-
ature (Monaghan and Cotman, 1982). After 30 min, the
slides were dipped quickly in water and air-dried using
the “cool” setting of a blow dryer. The [3H]kainate was
diluted to 12 nM (;3 3 Kd) using 50 mM Tris-citrate.
For each animal, two slides were incubated with
[3H]kainate to determine total binding and one slide
with [3H]kainate plus 10 mM CNQX to determine non-
specific binding. The slides were incubated for 30 min
at 4°C. After incubation, the slides were washed for 10
sec each in three 4°C washes of 50 mM Tris-citrate,
then quickly dipped in 4°C water and air-dried using
the “cool” setting of a blow dryer. The slides were
placed in autoradiography cassettes and apposed to
Amersham [3H]Hyperfilm for 3 weeks.
Image and data analyses
Film was developed and used for quantitative, com-
puter image analysis (with NIH Image 1.56), as previ-
ously described (Meador-Woodruff et al., 1997). For in
situ hybridization, tissue background was subtracted
from total gray scale values (GSV) for the cell body
layers of dentate gyrus and CA1–CA4 and for receptor
autoradiography nonspecific binding was subtracted
from total binding in cellular and dendritic layers of
dentate gyrus and CA1–CA4. These hippocampal re-
gions were identified using an atlas of the rat brain
(Paxinos and Watson, 1982). Left and right side values
were pooled, as were values for duplicate slides, pro-
viding one averaged GSV per region per animal. The
corrected average GSV was converted into optical den-
sity (OD). In Experiment 1, OD values for each probe or
binding site were analyzed in Statistica 4.1 using
three-way ANOVA, with treatment, duration of treat-
ment, and region as the independent variables. Post-
hoc comparisons were performed using Newman-Kuels
test. For several analyses, there were missing values in
the 5-day treatment group; mean substitution was uti-
lized for these missing data points prior to statistical
analyses. In Experiment 2, OD values for each probe or
binding site were analyzed in Statview 4.01 using two-
way ANOVA, with treatment and region as the inde-
pendent variables. Post-hoc comparisons were per-
formed using the Scheffe test.
RESULTS
All NMDA, AMPA, and kainate receptor subunit
mRNAs were detected in the hippocampal formation
(Figs. 1, 2), except NR2C mRNA, which was not con-
sistently expressed above background levels under con-
ditions used for these experiments; this is in agreement
with previous work (Wheal and Thomson, 1995; Mea-
dor-Woodruff et al., 1997). Similarly, the six binding
sites were visualized in hippocampal formation (Figs.
1, 2).
Experiment 1 (MK-801 time course)
NMDA receptor regulation
There was no main effect for treatment on any of the
four subunit mRNAs (Fig. 3). There was a main effect
for duration of treatment for NR2B (F3,21 5 3.47; P ,
0.05). Post-hoc analysis revealed that values from 10
days of treatment differed significantly from the other
three treatment times (all P , 0.05). There were sig-
nificant treatment by duration interactions for both
NR2A (F6,36 5 2.65; P , 0.05) and NR2B (F6,36 5 2.59;
P , 0.05); however, there were no significant differ-
ences between treatments and controls for the same
duration of treatment. There were several significant
findings for NMDA receptor binding sites in this exper-
iment (Fig. 4). [3H]MK-801 binding was significantly
decreased by MK-801 treatment (F2,12 5 54.75; P ,
0.0001). Post-hoc tests demonstrated that both doses of
MK-801 differed from control (both P , 0.001), as well
as from each other (P , 0.05). There was a main effect
for treatment on [3H]ifenprodil binding (F2,12 5 10.21;
P , 0.005), with low dose MK-801 treatment signifi-
cantly differing from high dose and control (both P ,
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Fig. 1. Distribution of NMDA receptor subunit mRNAs and binding sites in the rat hippocampus.
R2C subunit mRNA levels were not consistently above background.
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0.05). Further, there was a significant treatment by
duration interaction for the expression of this binding
site (F6,36 5 3.97; P , 0.005); acute high dose MK-801
treatment differed from acute and 5-day low dose treat-
ment, while 5-day control treatment differed from acute
and 5-day low dose treatment (all P , 0.05). There was a
main effect for treatment on [3H]CGP39653 binding
(F2,12 5 3.47; P , 0.05), with low dose MK-801 treatment
significantly differing from high dose and control (both
P , 0.05). There were no significant differences for
[3H]MDL105,519 binding.
Kainate receptor regulation
There was no main effect for treatment on any of
the five subunit mRNAs, nor were there any signifi-
cant interactions. There was no main effect of treat-
ment on [3H]kainate binding, although there was a
significant treatment by region interaction (F6,24 5
2.57; P , 0.05) (these data are not presented graph-
ically).
AMPA receptor regulation
There was no main effect for treatment on any of
the four subunit mRNAs, although there were signif-
icant treatment by duration (F6,24 5 3.08; P , 0.05)
and treatment by region (F8,32 5 3.91; P , 0.005)
interactions for gluR4 expression (data not shown).
[3H]AMPA binding expression was not affected by
either treatment (these data are not presented
graphically).
Fig. 2. Distribution of AMPA and kainate receptor subunit mRNAs and [3H]AMPA and [3H]kainate
binding sites in the rat hippocampus. GluR6 subunit mRNA levels were not consistently above back-
ground.
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Experiment 2 (AMPA/kainate receptor
modulators)
NMDA receptor regulation
There was a main effect for treatment for NR2B
mRNA levels (F5,53 5 13.47; P , 0.0001) (Fig. 5). Post-
hoc analysis revealed that aniracetam, CNQX, and
GYKI52466 treatments each differed from control (all
P , 0.05). For all five treatments, there were signifi-
cant treatment by region interactions (F20,212 5 20.49;
P , 0.0001) for NR2B mRNA expression (Fig. 5). No
other subunit mRNA was significantly affected by the
treatments in this experiment. There were several sig-
nificant findings for NMDA receptor binding sites in
this experiment. There was a main effect for treatment
on [3H]MK-801 binding (F5,53 5 24.66; P , 0.0001);
post-hoc tests demonstrated that all five treatments
Fig. 3. The effects of 1, 2, 5, or 10 daily
injections of MK-801 on NMDA receptor sub-
unit mRNA levels in the dentate gyrus and
hippocampus. Data are expressed as optical
density 6 SEM for five animals. There was
no main effect for treatment on any of the
four subunit mRNAs. There was a significant
treatment by duration interaction for NR2A,
and post-hoc analysis revealed that low dose
MK-801 treatment differed from high dose
(*P , 0.05). Film exposure times varied for
each probe and binding site, so direct com-
parisons of optical density values between
probes or binding sites should not be made.
Fig. 4. The effects of 1, 2, 5, or 10 daily
injections of MK-801 on NMDA receptor
binding site levels in the dentate gyrus and
hippocampus. Data are expressed as optical
density 6 SEM for five animals. There was a
main effect for treatment on [3H]ifenprodil
binding, with low dose MK-801 treatment
significantly differing from high dose and
control (both P , 0.05). There were no signif-
icant differences for [3H]MDL105,519 bind-
ing. [3H]MK-801 binding was significantly
decreased by MK-801 treatment. Post-hoc
tests demonstrated that both doses of MK-
801 differed from control (both P , 0.001), as
well as from each other (P , 0.05). There was
a main effect for treatment on [3H]CGP39653
binding (F2,12 5 3.47; P , 0.05), with low dose
MK-801 treatment significantly differing
from high dose and control (both P , 0.05).
Film exposure times varied for each probe
and binding site, so direct comparisons of
optical density values between probes or
binding sites should not be made.
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induced significant increases (all P , 0.01), compared
to vehicle. There was a main effect for treatment on
[3H]ifenprodil binding (F5,53 5 8.50; P , 0.0001), with
aniracetam (P , 0.0001) and GYKI52466 (P , 0.005)
treatments significantly differing from control. There
were no significant differences for [3H]CGP39653 or
[3H]MDL105,519 binding.
Kainate receptor regulation
There was a main effect for treatment for each of the
three low affinity kainate receptor subunit mRNAs
(gluR5: F5,53 5 5.50; P , 0.0001; gluR6: F5,53 5 6.53;
P , 0.0001; gluR7: F5,53 5 3.56; P , 0.005). Post-hoc
analysis showed that aniracetam treatment caused a
significant decrease in gluR5 mRNA (P , 0.005) and a
significant increase in gluR7 mRNA (P , 0.05), relative
to control, while NBQX treatment resulted in a signif-
icant increase in gluR7 mRNA (P , 0.05). None of the
five treatments caused significant alterations in gluR6
mRNA levels, relative to control. There was no main
effect for treatment on KA1 and KA2, but there was a
significant main effect for [3H]kainate binding F5,53 5
4.38; P , 0.001). However, none of the five treatments
caused significant alterations in [3H]kainate binding
relative to control. There were no significant treatment
by region interactions for any markers of kainate re-
ceptor expression.
AMPA receptor regulation
There was no main effect for treatment on any of the
four subunit mRNAs or [3H]AMPA binding, except for
a significant main effect for treatment on gluR1 mRNA
Fig. 5. The effects of seven daily injec-
tions of aniracetam (A), CNQX (C),
GYKI52466 (G), NBQX (N), or riluzole (R) on
NMDA receptor expression in the dentate gy-
rus and hippocampus. Data are expressed as
percent change from control 6 SEM for 10
animals. *Significantly different from control
(P , 0.05).
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levels (F5,53 5 5.01; P , 0.0005); NBQX treatment
caused a significant decrease in this subunit mRNA
(P , 0.05) (neither these AMPA nor kainate data are
shown graphically).
DISCUSSION
NMDA receptor expression was more sensitive to
regulation in these experiments than either AMPA or
kainate receptors, even by direct antagonists of non-
NMDA ionotropic receptors. However, the regulation of
NMDA receptor expression was limited to one subunit
mRNA and two binding sites, suggesting that there is
selectivity in the effects.
All five drugs in Experiment 2 caused an upregula-
tion of [3H]MK-801 binding, while MK-801 treatment
caused a downregulation. In our studies, we were not
able to detect whether the change in binding reflected
a change in total number of receptors or a change in
affinity. The lack of a concomitant decrease in glycine
or glutamate binding in either experiment argues
against a change in total receptor number. There are
several potential mechanisms for a change in PCP site
affinity. For example, the NR1 subunits containing
exon 5 have been shown to have higher affinity for
[3H]MK-801 (Rodriguez-Paz et al., 1995), so perhaps a
downward shift in exon 5-containing NR1 subunits
resulted from MK-801 treatment, and/or an upward
shift is associated with the treatments in Experiment
2. Because we measured total NR1 mRNA, the present
study could not detect these changes. Alternatively,
PCP site affinity decreases with the inclusion of NR2C
or NR2D subunits, in place of NR2A or NR2B (Lynch et
al., 1994); perhaps there was a shift in receptor com-
position not detectable at the level of mRNA expres-
sion. Less likely is the possibility that residual MK-801
was not washed off during receptor autoradiography in
Experiment 1 and competed with [3H]MK-801. How-
ever, sections were washed under conditions that open
NMDA receptor ion channels, which allows for the
dissociation of residual MK-801 prior to the addition
[3H]MK-801 (Huettner and Bean, 1988). Further, there
was no difference between the low and high dose ani-
mals, which might be expected if residual MK-801 was
competing with [3H]MK-801.
Similarly, the increases in both [3H]ifenprodil bind-
ing and [3H]MK-801 binding seen in Experiment 2 may
be parsimoniously explained by an increase in NR2B
incorporation into final assembled receptors, but only if
the previous population contained proportionately
more NR2C or NR2D. A shift toward NR2B from NR2C
or NR2D would not only increase the affinity of NMDA
receptors for MK-801 (as manifested by an increase in
[3H]MK-801 binding) (Lynch et al., 1994), but would
also increase affinity for ifenprodil (Williams, 1997).
Further, these NR2B-containing receptors might be
more sensitive to the antipsychotic haloperidol (Ilyin et
al., 1996); it is tempting to speculate that certain glu-
tamatergic compounds may be used as an adjunct to
antipsychotic treatment to alter the potency of anti-
psychotics at NMDA receptors. Conversely, a change in
exon 5-containing NR1 subunit expression probably
cannot account for changes in both [3H]ifenprodil and
[3H]MK-801 binding. While the inclusion of this exon
increases the affinity for MK-801 (Rodriguez-Paz et al.,
1995), it actually decreases spermine potentiation in
vitro (Durand et al., 1993). While ifenprodil apparently
does not label the polyamine site, but rather a modu-
latory site of the polyamine site, it might still be ex-
pected that these receptors would have a lower affinity
for ifenprodil (Gallagher et al., 1996; Legendre and
Westbrook, 1991; Reynolds and Miller, 1989).
GYKI52466 and aniracetam treatments resulted in
significant increases in [3H]ifenprodil binding; these
drugs also caused a decrease in NR2B mRNA. The
presence of this subunit in assembled NMDA receptors
is associated with increased affinity for ifenprodil (Gal-
lagher et al., 1996; Williams, 1997). If protein levels of
NR2B are also decreased, then these data would be the
opposite of what would be expected. Data for lower dose
MK-801 treatment from Experiment 1 may clarify this
result (Figs. 3, 4); [3H]ifenprodil binding peaks on day
5 and returns to baseline by day 10, while NR2B
mRNA reaches its nadir at day 5, but also returns to
baseline by day 10. This suggests that there is a post-
transcriptional increase in NR2B protein synthesis, or
increased inclusion of NR2B from the cytoplasmic pool
into the final receptors; these processes may result in
increased [3H]ifenprodil binding that peaks around 5
days. During the rise in [3H]ifenprodil binding, feed-
back mechanisms may occur at the transcriptional
level that drive down [3H]ifenprodil binding by de-
creasing NR2B synthesis. By day 10, both [3H]ifen-
prodil and NR2B mRNA levels are back to baseline.
Obviously, NR2B protein levels and more time points
would need to be measured to test this hypothesis, but
it is one way to explain the dissociation between
[3H]ifenprodil binding and NR2B mRNA levels seen for
GYKI52466 and aniracetam treatments.
Aniracetam and GYKI52466 would not be expected
to cause similar effects on glutamate receptor expres-
sion, given that they have opposite effects on AMPA
receptor desensitization (Bleakman and Lodge, 1998).
One recent study, however, suggests that aniracetam
may have paradoxical effects that may depend on in-
trinsic hippocampal circuitry. Concomitant aniracetam
treatment (3–5 mM) prevented NMDA-induced hip-
pocampal neurotoxicity in vitro (Pizzi et al., 1995),
which does not appear to be due to a direct effect of
aniracetam on the NMDA receptor (Martin and
Haefely, 1993). This was unexpected, considering that
the increased AMPA receptor activity putatively in-
duced by aniracetam would be expected to exacerbate
excitotoxicity. It is unclear whether the effects of
aniracetam are mediated by presynaptic or postsynap-
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tic AMPA receptors, and perhaps our findings are re-
lated to differential effects of GYKI52466 and anirac-
etam on different populations of AMPA receptors
(Patel and Croucher, 1997).
AMPA receptor expression was minimally affected,
even by direct antagonists, at the levels of total subunit
mRNA and [3H]AMPA binding. NBQX, GYKI52466,
and CNQX would all be expected to induce an upregu-
lation of AMPA receptors, given their potent AMPA
receptor antagonist properties. Perhaps the complex
intrisinic circuitry of the hippocampus mitigates ex-
pected increases in AMPA receptor expression after
antagonist treatment.
Similarly, kainate receptor expression was also only
modestly affected. None of the five treatments in Ex-
periment 2 altered [3H]kainate binding, while MK-801
induced only a significant treatment by region interac-
tion (consistent with Gao and Tamminga, 1995).
CNQX, the drug for which kainate receptors have the
highest affinity in this study, did not significantly alter
kainate receptor expression. Surprisingly, aniracetam
had the greatest effect on kainate receptor expression.
If mRNA levels reflect protein levels, then aniracetam
may be inducing a shift in kainate receptor composi-
tion. GluR5 homomers in vitro are activated by gluta-
mate but desensitize quickly (Sommer et al., 1992),
while gluR7 homomers have been shown to display
very low affinity for glutamate (Schiffer et al., 1997).
The net effect of this shift from gluR5- to gluR7-con-
taining receptors may be to make kainate receptors
less responsive to glutamate. Kainate receptors have
been shown to decrease GABAergic inhibition, so de-
creases in kainate receptor activity may result in a
relative increase in GABAergic activity (Clarke et al.,
1997; Frerking et al., 1998; Rodriguez-Moreno et al.,
1997). Aniracetam presumably increases postsynaptic
AMPA receptor activity, so the shift in kainate receptor
expression may represent a feedback mechanism that
increases GABAergic inhibition to prevent AMPA re-
ceptor-mediated hyperexcitability.
For the most part, GYKI52466, CNQX, and NBQX
treatments produced similar patterns of glutamate re-
ceptor expression in hippocampus. This would suggest
that these drugs have a common effect, namely, AMPA
receptor antagonism. CNQX and NBQX both antago-
nize AMPA receptors by a different mechanism than
GYKI52466, which may explain some subtle differ-
ences between the effects of these drugs.
Aniracetam was the only positive modulator in either
experiment, and seemed to induce the most dramatic
effects on NMDA and kainate receptor expression. This
might suggest that glutamatergic hyperactivity is a
stronger impetus than hypoactivity to regulate glutamate
receptor expression. Again, it is surprising that these
putative feedback mechanisms did not affect AMPA re-
ceptor expression. Alternatively, aniracetam may have
exerted its effects through a cholinergic mechanism
(Pepeu and Spignoli, 1989). However, seven daily injec-
tions of the acetylcholinesterase inhibitor tacrine resulted
in decreased hippocampal AMPA receptor expression,
but no change in kainate or NMDA receptor expression
(Sihver et al., 1997). These results are in direct contrast
to our data, strongly arguing against a cholinergic mech-
anism for the effects of aniracetam in our study.
Hippocampal NMDA receptor expression was more
sensitive to regulation than AMPA and kainate recep-
tors expression, even by direct AMPA and kainate re-
ceptor antagonists. Our data suggest that ionotropic
glutamate receptors interact at the level of receptor
expression; there may be common adaptive mecha-
nisms, associated with changes in NMDA receptor ex-
pression, that result from altered glutamatergic activ-
ity. These adaptions may be useful for the design of
novel therapies for dementias, epilepsy, and schizo-
phrenia. Conversely, these data also suggest that drug
regimens that attempt to target one ionotropic gluta-
mate receptor subtype may indirectly affect other sub-
types, potentially producing unwanted side effects.
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